Search research articles
Contact Us
Filters
Showing results (161-170 of 201) with videos related to
Page
of 21
Sort By:
The Oncologist
|
December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.
Hepatology (Baltimore, Md.)
|
May 17, 2021
REPLY
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
The Oncologist
|
March 27, 2019
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study
Angela Lamarca, Joakim Crona, Maxime Ronot, et al.
Journal of Hepatology
|
July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study
Do-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.
Hepatology (Baltimore, Md.)
|
February 7, 2021
REPLY
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
Neuroendocrinology
|
July 28, 2020
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability
Clarisse Dromain, Anders Sundin, Pavan Najran, et al.
Hepatology (Baltimore, Md.)
|
October 19, 2020
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
Cancers
|
August 27, 2021
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
Melissa Frizziero, Alice Durand, Rodrigo G Taboada, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 12, 2018
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
Muhammad Ahsan Javed, Georg Beyer, Nha Le, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Angela Lamarca, Maxime Ronot, Salma Moalla, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 201) with videos related to
Sort By:
Page
of 21
The Oncologist
|
December 10, 2020
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, et al.
Hepatology (Baltimore, Md.)
|
May 17, 2021
REPLY
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
The Oncologist
|
March 27, 2019
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study
Angela Lamarca, Joakim Crona, Maxime Ronot, et al.
Journal of Hepatology
|
July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study
Do-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.
Hepatology (Baltimore, Md.)
|
February 7, 2021
REPLY
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
Neuroendocrinology
|
July 28, 2020
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability
Clarisse Dromain, Anders Sundin, Pavan Najran, et al.
Hepatology (Baltimore, Md.)
|
October 19, 2020
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, et al.
Cancers
|
August 27, 2021
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
Melissa Frizziero, Alice Durand, Rodrigo G Taboada, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 12, 2018
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
Muhammad Ahsan Javed, Georg Beyer, Nha Le, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Angela Lamarca, Maxime Ronot, Salma Moalla, et al.
Page
of 21